Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 2, Issue 11, pp. 1036-1047
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 23, 2011
- Revision received July 23, 2012
- Accepted July 31, 2012
- Published first August 22, 2012.
Article Versions
- Previous version (August 22, 2012 - 05:26).
- Previous version (August 24, 2012 - 07:28).
- Previous version (October 23, 2012 - 13:02).
- Previous version (October 25, 2012 - 10:55).
- You are viewing the most recent version of this article.
Copyright & Usage
©2012 American Association for Cancer Research.
Author Information
- Yasir H. Ibrahim1,
- Celina García-García1,
- Violeta Serra1,
- Lei He6,7,
- Kristine Torres-Lockhart6,
- Aleix Prat5,
- Pilar Anton1,
- Patricia Cozar1,
- Marta Guzmán1,
- Judit Grueso1,
- Olga Rodríguez1,
- Maria Teresa Calvo1,
- Claudia Aura2,
- Orland Díez4,
- Isabel T. Rubio3,
- José Pérez4,
- Jordi Rodón4,
- Javier Cortés4,
- Leif W. Ellisen6,7,
- Maurizio Scaltriti6,7 and
- José Baselga1,6,7
- Authors' Affiliations:1Experimental Therapeutics Laboratory, 2Molecular Pathology, 3Breast Surgical Oncology, 4Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, Barcelona, Spain; 5Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 6Massachusetts General Hospital Cancer Center, Massachusetts General Hospital; and 7Harvard Medical School, Boston, Massachusetts
- Corresponding Authors:
José Baselga, Massachusetts General Hospital Cancer Center, 10 North Grove Street, LRH-1, Boston, MA 02114. Phone: 617-726-2408; Fax: 617-643-9686; E-mail: jbaselga{at}partners.org; and Maurizio Scaltriti, Massachusetts General Hospital Cancer Center, Harvard Medical School, CNY 149, 13th Street, Charlestown, MA 02129. Phone: 617-643-8239; Fax: 617-724-7298; E-mail: mscaltriti{at}partners.org
November 2012
Volume 2, Issue 11
Volume 2, Issue 11
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Jump to section
Advertisement